Fingolimod: brain volume data

As a follow-up to my comment on a previous posting; I predict that if the PPMS trial is positive Fingolimod will be the first drug to be licensed as a neuroprotective therapy in MS.

The following diagram summarises the MRI data published on the impact of Fingolimod on brain atrophy over 2 years.

Please see: Kappos et al. N Engl J Med. 2010 Feb 4;362(5):387-401.

COI: Please note my previous COI statement in relation to Fingolimod.